Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H20O2 |
| Molecular Weight | 172.2646 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCCC(C)(C)O)CC=O
InChI
InChIKey=WPFVBOQKRVRMJB-UHFFFAOYSA-N
InChI=1S/C10H20O2/c1-9(6-8-11)5-4-7-10(2,3)12/h8-9,12H,4-7H2,1-3H3
Hydroxycitronellal is a perfume ingredient with a medium strength floral scent, reminiscent of lily and sweet tropical melon. It is produced synthetically from naturally occurring scent chemical citronellal. It is on the CFR - Code of Federal Regulations Title 21 list of synthetic flavoring substances and adjuvants. Hydroxycitronellal is banned in the European Union because of its toxic properties. Hydroxycitronellal is an allergen. Hydroxycitronellal has being shown to consistently modulate CCR5, CCL27, CCL2 and CCR7 in immature dendritic cells. Hydroxycitronellal is a TRPM8 agonist.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3108632 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14757700 |
19.6 mM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | ESIKA EXPRESSION ANTIPERSPIRANT ROLL-ON DEODORANT Approved UseReduces underarm perspiration |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 3.0 |
inconclusive [IC50 23.9185 uM] | |||
Page: 4.0 |
inconclusive [IC50 37.9083 uM] | |||
Page: 54.0 |
no | |||
Page: 94.0 |
no | |||
Page: 80.0 |
no | |||
Page: 4.0 |
yes [IC50 37.9083 uM] | |||
Page: 6.0 |
yes [IC50 79.1862 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 79 | 82 |
no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 95.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. | 2015-06 |
|
| Effect of a microemulsion system on hapten-peptide reactivity studies: examples of hydroxycitronellal and citral, fragrance skin sensitizers, with glutathione. | 2010-09-20 |
|
| A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. | 2010-09 |
|
| Polyvalent type IV sensitizations to multiple fragrances and a skin protection cream in a metal worker. | 2009-06 |
|
| Atopic dermatitis and allergic reactions to individual fragrance chemicals. | 2009-02 |
|
| Use of an ex vivo local lymph node assay to assess contact hypersensitivity potential. | 2008-07 |
|
| A smelling trip into the past: the influence of synthetic materials on the history of perfumery. | 2008-06 |
|
| ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1. | 2008-03 |
|
| Allergic and photoallergic contact dermatitis from ketoprofen: evaluation of cross-reactivities by a combination of photopatch testing and computerized conformational analysis. | 2008 |
|
| Chemicals with weak skin sensitizing properties can be identified using low-density microarrays on immature dendritic cells. | 2007-11-01 |
|
| Fragrance ingredient labelling in products on sale in the U.K. | 2007-08 |
|
| High-performance liquid chromatographic method for the simultaneous determination of 24 fragrance allergens to study scented products. | 2007-07-27 |
|
| Sensitization to 26 fragrances to be labelled according to current European regulation. Results of the IVDK and review of the literature. | 2007-07 |
|
| Phenotypic alterations and cytokine production in THP-1 cells in response to allergens. | 2007-04 |
|
| GC-MS quantification of suspected volatile allergens in fragrances. 2. Data treatment strategies and method performances. | 2007-01-10 |
|
| Evaluation of phototoxic properties of fragrances. | 2007 |
|
| Determination of fragrance allergens in cosmetics by size-exclusion chromatography followed by gas chromatography-mass spectrometry. | 2006-11-03 |
|
| CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice. | 2006-04 |
|
| [Contact allergy to fragrances]. | 2006 |
|
| Correlations of patch test reactivity and the repeated open application test (ROAT)/provocative use test (PUT). | 2004-11 |
|
| Ethanol and diethyl phthalate: vehicle effects in the local lymph node assay. | 2004-06-19 |
|
| Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. | 2004-02 |
|
| A stronger patch test elicitation reaction to the allergen hydroxycitronellal plus the irritant sodium lauryl sulfate. | 2003-09 |
|
| The fragrance hand immersion study - an experimental model simulating real-life exposure for allergic contact dermatitis on the hands. | 2003-06 |
|
| Deodorants: an experimental provocation study with hydroxycitronellal. | 2003-04 |
|
| Application of the risk assessment paradigm to the induction of allergic contact dermatitis. | 2003-02 |
|
| Multicentre study of fragrance allergy in Hungary. Immediate and late type reactions. | 2002-06 |
|
| Sensitization methodology and primary prevention of the research institute for fragrance materials. | 2002 |
|
| Fragrance chemicals in domestic and occupational products. | 2001-10 |
|
| Characterization of T cell responses to fragrances. | 2001-05-01 |
|
| In vitro primary sensitization of hapten-specific T cells by cultured human epidermal Langerhans cells--a screening predictive assay for contact sensitizers. | 1996-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12786728
Deodorants containing hydroxycitronellal in the concentration range of 0.032-0.32% used twice daily on healthy skin in individuals hypersensitive to hydroxycitronellal can elicit axillary dermatitis in a few weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11312644
PHA-induced mitogenesis assays
revealed that Hydroxycitronellal could be applied to PBMC in final
concentrations of 0.1 to 100 ug/ml
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 172.515
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
||
|
JECFA EVALUATION |
HYDROXYCITRONELLAL
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N0000171131
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
7888
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
1362893
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000134068
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
DTXSID6042232
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
8SQ0VA4YUR
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
Hydroxycitronellal
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
53459
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
203-518-7
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
406740
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
466
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
C020755
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
SUB59505
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
8SQ0VA4YUR
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
DB14187
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY | |||
|
107-75-5
Created by
admin on Mon Mar 31 18:15:01 GMT 2025 , Edited by admin on Mon Mar 31 18:15:01 GMT 2025
|
PRIMARY |
ACTIVE MOIETY